Related references
Note: Only part of the references are listed.Resveratrol: A New Potential Therapeutic Agent for Melanoma?
Mohamad Hossein Pourhanifeh et al.
CURRENT MEDICINAL CHEMISTRY (2021)
Exosomes and Lung Cancer: Roles in Pathophysiology, Diagnosis and Therapeutic Applications
Atefeh Amiri et al.
CURRENT MEDICINAL CHEMISTRY (2021)
Nanomicellar-curcumin exerts its therapeutic effects via affecting angiogenesis, apoptosis, and T cells in a mouse model of melanoma lung metastasis
Rajab Mardani et al.
PATHOLOGY RESEARCH AND PRACTICE (2020)
The therapeutic potential of resveratrol in a mouse model of melanoma lung metastasis
Amirhossein Davoodvandi et al.
INTERNATIONAL IMMUNOPHARMACOLOGY (2020)
The therapeutic potential of human adipose-derived mesenchymal stem cells producing CXCL10 in a mouse melanoma lung metastasis model
Harried Mirzaei et al.
CANCER LETTERS (2018)
Application of Mesenchymal Stem Cells in Melanoma: A Potential Therapeutic Strategy for Delivery of Targeted Agents
Hamed Mirzaei et al.
CURRENT MEDICINAL CHEMISTRY (2016)
Inhibition of Topoisomerase (DNA) I (TOP1): DNA Damage Repair and Anticancer Therapy
Yang Xu et al.
BIOMOLECULES (2015)
The involvement of Notch signaling in melanoma vasculogenic mimicry
Amalia Vartanian et al.
CLINICAL AND EXPERIMENTAL MEDICINE (2013)
A phase I study of rebeccamycin analog in combination with oxaliplatin in patients with refractory solid tumors
Charles J. Nock et al.
INVESTIGATIONAL NEW DRUGS (2011)
VEGFR1 and PKCα signaling control melanoma vasculogenic mimicry in a VEGFR2 kinase-independent manner
Amalia Vartanian et al.
MELANOMA RESEARCH (2011)
Mechanisms of resistance to antiangiogenesis therapy
Faisal Azam et al.
EUROPEAN JOURNAL OF CANCER (2010)
Enzastaurin, an oral serine/threonine kinase inhibitor, as second- or third-line therapy of non-small-cell lung cancer
Yun Oh et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Akt-dependent transformation: there is more to growth than just surviving
DR Plas et al.
ONCOGENE (2005)
Discovery of a fluoroindolo[2,3-a]carbazole clinical candidate with broad spectrum antitumor activity in preclinical tumor models superior to the marketed oncology drug, CPT-11
MG Saulnier et al.
JOURNAL OF MEDICINAL CHEMISTRY (2005)
Molecular plasticity of human melanoma cells
MJC Hendrix et al.
ONCOGENE (2003)
Share Paper
